Comparing Aflibercept 8 mg and Faricimab in RVO

In this segment, the panel compares the pivotal QUASAR trial of aflibercept 8 mg in retinal vein occlusion (RVO) with the BALATON and COMINO trials evaluating faricimab. They note that all three studies demonstrated robust visual and anatomic improvements—typically gains of three or more lines of vision—particularly when treatment began early and was delivered consistently. The panel emphasizes that outcomes are largely determined by disease severity and timing of intervention, with ischemic CRVO cases showing more limited recovery. Expert faculty highlight that both faricimab and aflibercept 8 mg offer strong efficacy and potential durability advantages, though cross-trial comparisons remain imperfect. Ultimately, they explains, treatment selection will depend on individual patient characteristics and forthcoming FDA labeling. The discussion concludes with agreement that newer-generation anti-VEGF agents have advanced care for macular edema secondary to RVO, offering comparable outcomes with the possibility of longer treatment intervals.